Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).
Clinical, bronchoscopic, spirographic, scintigraphic, and chemical analyses were done in 24 children with cystic fibrosis to assess the mucolytic effects of acetylcysteine inhalations versus L-arginine hydrochloride aerosols. The latter drug is less active than acetylcysteine and should not be used to treat children with cystic fibrosis.
D000111:Acetylcysteine / Q000008:administration & dosage* / Q000627:therapeutic use; D000336:Aerosols; D001120:Arginine / Q000008:administration & dosage* / Q000627:therapeutic use; D001999:Bronchoscopy; D002245:Carbon Dioxide / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003371:Cough; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D005100:Expectorants / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009093:Mucus / Q000378:metabolism; D010100:Oxygen / Q000097:blood; D011877:Radionuclide Imaging; D012119:Respiration; D012129:Respiratory Function Tests; D013147:Spirometry; D013183:Sputum / Q000382:microbiology
D000336:Aerosols; D005100:Expectorants; D002245:Carbon Dioxide; D001120:Arginine; D010100:Oxygen; D000111:Acetylcysteine